Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
Medtronic
Colorcon
Dow

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Ifetroban

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Ifetroban?

Ifetroban is an investigational drug.

There have been 9 clinical trials for Ifetroban. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2014.

The most common disease conditions in clinical trials are Respiratory Tract Diseases, Respiration Disorders, and Hypertension. The leading clinical trial sponsors are Cumberland Pharmaceuticals, Brigham and Women's Hospital, and Jeffrey Rade.

There are six hundred and forty-eight US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Ifetroban
TitleSponsorPhase
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionAmerican Heart AssociationPhase 2
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionCumberland PharmaceuticalsPhase 2
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionJeffrey RadePhase 2

See all Ifetroban clinical trials

Clinical Trial Summary for Ifetroban

Top disease conditions for Ifetroban
Top clinical trial sponsors for Ifetroban

See all Ifetroban clinical trials

US Patents for Ifetroban

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ifetroban   Start Trial Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
Ifetroban   Start Trial Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer Capella Therapeutics, Inc. (San Diego, CA)   Start Trial
Ifetroban   Start Trial Compositions and methods of treating cardiac fibrosis with ifetroban Cumberland Pharmaceuticals Inc. (Nashville, TN) Vanderbilt University (Nashville, TN)   Start Trial
Ifetroban   Start Trial Substituted biaryl sulfonamides and the use thereof NovoMedix, LLC (San Diego, CA)   Start Trial
Ifetroban   Start Trial Compositions and methods of treating muscular dystrophy with thromboxane-A.sub.2 receptor antagonists Cumberland Pharmaceuticals, Inc. (Nashville, TN) Vanderbilt University (Nashville, TN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ifetroban

Drugname Country Document Number Estimated Expiration Related US Patent
Ifetroban China 103987697 2031-10-14   Start Trial
Ifetroban European Patent Office 2766345 2031-10-14   Start Trial
Ifetroban European Patent Office 2899183 2031-10-14   Start Trial
Ifetroban Spain 2572908 2031-10-14   Start Trial
Ifetroban Spain 2699226 2031-10-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Harvard Business School
Express Scripts
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.